Arcalyst Injection, Powder, Lyophilized, For Solution
Product Images NDC 73604-914

35 FDA label images from Kiniksa Pharmaceuticals (uk), Ltd. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Arcalyst (NDC 73604-914). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kiniksa Pharmaceuticals (uk), Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Arcalyst 01)

Figure 1 (Arcalyst 01)
A line graph depicting the Group Mean Daily Key Symptom Score over Study Weeks comparing ARCALYST and Placebo treatments. The timeline is divided into three phases: Part A Baseline (no treatment), Part A Double-blind ARCALYST vs. Placebo, and Single-blind ARCALYST Treatment Phase. ARCALYST treatment scores decrease notably compared to placebo during the Double-blind phase, with scores converging during the Single-blind phase.*
FDA Label Image

Figure 2 (Arcalyst 02)

Figure 2 (Arcalyst 02)
A line graph depicting mean Pain NRS scores and CRP levels over 12 weeks (W1-W12) and baseline (BL) to day 4 (D4) in patients receiving Arcalyst. The graph shows a decrease in Pain NRS mean values and CRP mean values over time, with corresponding patient counts and data tables for each time point below the graph.*
FDA Label Image

Figure 3 (Arcalyst 03)

Figure 3 (Arcalyst 03)
A Kaplan-Meier survival curve chart comparing the probability of no pericarditis recurrence over time (weeks) between ARCALYST (rilonacept) and placebo groups. The ARCALYST group shows a higher probability of no recurrence, with the x-axis labeled as Time (weeks) and y-axis as Probability of No Pericarditis Recurrence (%). The chart includes a statistical summary with hazard ratio and p-value, as well as a table indicating the number of subjects at risk at various time points for both groups.*
FDA Label Image

Figure A (Arcalyst 04)

Figure A (Arcalyst 04)
Packaging label for Arcalyst (rilonacept) injection, 220 mg per vial. The label specifies this is a lyophilized powder for subcutaneous injection, requiring reconstitution and refrigeration at 2°C to 8°C (36°F to 46°F). The labeler is Kiniksa Pharmaceuticals (UK), Ltd. The package contains one single-dose vial and includes storage and handling instructions.*
FDA Label Image

Figure B (Arcalyst 05)

Figure B (Arcalyst 05)
Packaging label for Arcalyst injection powder, lyophilized, for solution containing rilonacept. The label indicates a strength of 220 mg per vial for subcutaneous use only. The label states it must be reconstituted and stored refrigerated at 2°C to 8°C (36°F to 46°F) until use. The packaging contains four single-dose vials. Manufactured by Kiniksa Pharmaceuticals (UK), Ltd.*
FDA Label Image

Figure C (Arcalyst 06)

Figure C (Arcalyst 06)
An instructional illustration showing a person's hands removing a protective seal or cap from a vial, likely demonstrating the preparation step before using an injection product such as Arcalyst (rilonacept) lyophilized powder for solution.*
FDA Label Image

Figure D (Arcalyst 07)

Figure D (Arcalyst 07)
An instructional illustration showing hands pulling apart a cap or cover from a syringe or similar device, demonstrating how to remove the protective seal. The image emphasizes the action with arrows indicating the direction of pulling on each side.*
FDA Label Image

Figure E (Arcalyst 08)

Figure E (Arcalyst 08)
An instructional illustration showing hands preparing a syringe with a vial or stopper, demonstrating how to unlock or twist the syringe cap or plunger before use. No text or labeling is visible.*
FDA Label Image

Figure F (Arcalyst 09)

Figure F (Arcalyst 09)
An instructional illustration showing hands drawing 2.3 mL of liquid into a syringe, with a close-up inset magnifying the syringe's liquid measurement markings between 2.0 and 2.5 mL.*
FDA Label Image

Figure G (Arcalyst 10)

Figure G (Arcalyst 10)
An instructional illustration showing a hand inserting a syringe needle into a vial, with the other hand holding the vial. A downward arrow indicates the direction for inserting the needle, likely depicting the preparation of an injection solution.*
FDA Label Image

Figure H (Arcalyst 11)

Figure H (Arcalyst 11)
An instructional illustration showing a person drawing 2.3 mL of liquid from a vial into a syringe. The close-up inset highlights the volume marking between 2.0 and 2.5 mL on the syringe barrel, indicating the correct amount to withdraw.*
FDA Label Image

Figure I (Arcalyst 12)

Figure I (Arcalyst 12)
An illustration showing a syringe connected to a vial. A magnified inset highlights the syringe measurement, indicating a 2.3 mL volume drawn into the syringe, likely representing preparation for subcutaneous injection of Arcalyst (rilonacept) injection, powder, lyophilized, for solution.*
FDA Label Image

Figure J (Arcalyst 13)

Figure J (Arcalyst 13)
An instructional illustration showing two hands preparing an injection. One hand holds a vial, while the other hand inserts a syringe needle into the vial, demonstrating the step of drawing medication from the vial for subcutaneous injection.*
FDA Label Image

Figure K (Arcalyst 14)

Figure K (Arcalyst 14)
An instructional illustration showing a vial, a syringe, and a needle connected by arrows to the opening of a vial cap, likely demonstrating the preparation or assembly steps for a subcutaneous injection of Arcalyst (rilonacept) powder for solution.*
FDA Label Image

Figure L (Arcalyst 15)

Figure L (Arcalyst 15)
An instructional illustration showing a hand holding and shaking a vial or container, accompanied by a stopwatch indicating 1 minute, suggesting the vial should be shaken for one minute before use.*
FDA Label Image

Figure M (Arcalyst 16)

Figure M (Arcalyst 16)
Illustration comparing two vials of injection powder for Arcalyst (rilonacept) 160 mg/2 mL: the vial on the left is clear and free of particles, indicating the correct appearance, while the vial on the right shows particles or clumps inside, representing an incorrect or unacceptable appearance before reconstitution.*
FDA Label Image

Figure N (Arcalyst 17)

Figure N (Arcalyst 17)
An instructional illustration showing two hands preparing a vial by removing a protective cap. The left hand is peeling off a foil seal from the vial held in the right hand, indicating a step in the preparation of an injectable medication.*
FDA Label Image

Figure O (Arcalyst 18)

Figure O (Arcalyst 18)
An instructional illustration showing two hands pulling apart the ends of a plastic or rubber Y-shaped connector. The arrows indicate outward pulling motion on both sides, suggesting disconnection of the device.*
FDA Label Image

Figure P (Arcalyst 19)

Figure P (Arcalyst 19)
An instructional illustration showing a pair of hands operating a syringe, with one hand holding the syringe barrel and the other hand twisting the plunger, indicating how to use the injection device.*
FDA Label Image

Figure Q (Arcalyst 20)

Figure Q (Arcalyst 20)
An instructional illustration showing two hands preparing an injection syringe, likely related to the subcutaneous administration of Arcalyst (rilonacept) injection, powder, lyophilized, for solution.*
FDA Label Image

Figure R (Arcalyst 21)

Figure R (Arcalyst 21)
An instructional illustration showing two hands preparing an injection by inserting a syringe needle into a vial. The vial is held by the lower hand, while the upper hand pushes the syringe downward into the vial's rubber stopper.*
FDA Label Image

Figure S (Arcalyst 22)

Figure S (Arcalyst 22)
An instructional illustration showing two hands preparing a syringe for injection. One hand holds the syringe barrel while the other hand adjusts the plunger, demonstrating how to fill or expel air from the syringe.*
FDA Label Image

Figure T (Arcalyst 23)

Figure T (Arcalyst 23)
An instructional illustration showing two hands preparing a syringe. One hand holds the syringe barrel with a scale, and the other hand is adjusting the plunger. An arrow points to the plunger, indicating proper positioning or adjustment. The image likely relates to the preparation or administration of an injectable medication.*
FDA Label Image

Figure U (Arcalyst 24)

Figure U (Arcalyst 24)
Instructional diagram showing a step-by-step guide for preparing or using a syringe. The sequence depicts hands manipulating a syringe by inserting a needle or cartridge, pulling back on the plunger, and preparing the syringe for injection or medication administration.*
FDA Label Image

Figure V (Arcalyst 25)

Figure V (Arcalyst 25)
An instructional illustration showing hands pulling apart a flat, possibly sealed, strip or package along the indicated arrows, demonstrating how to open it. The image likely relates to the preparation or handling of a pharmaceutical product.*
FDA Label Image

Figure W (Arcalyst 26)

Figure W (Arcalyst 26)
An instructional illustration showing two hands preparing a syringe injection. One hand holds the syringe, and the other hand is positioned to twist the syringe cap, demonstrating the removal or attachment process. No text is visible.*
FDA Label Image

Figure X (Arcalyst 27)

Figure X (Arcalyst 27)
Illustration showing a vial and a syringe needle above the opening of a medication cartridge or device, with arrows indicating how the vial and needle are intended to be inserted or connected into the cartridge/device for preparation or administration of the drug.*
FDA Label Image

Figure Y (Arcalyst 28)

Figure Y (Arcalyst 28)
An instructional illustration showing proper subcutaneous injection sites on the human body. The front view highlights the abdomen and both thighs, and the back view shows the outer upper arms as recommended injection areas.*
FDA Label Image

Figure Z (Arcalyst 29)

Figure Z (Arcalyst 29)
An instructional illustration showing a hand pinching the skin on the abdomen, with two black arrows indicating the pinch area. The image likely demonstrates how to prepare the subcutaneous injection site for Arcalyst (rilonacept) injection.*
FDA Label Image

Figure Aa (Arcalyst 30)

Figure Aa (Arcalyst 30)
An instructional illustration showing the technique of administering an injection subcutaneously at a 90-degree angle. The image depicts one hand holding a syringe oriented perpendicular to the skin and the other hand pinching the injection site, demonstrating proper injection positioning likely associated with the Arcalyst (rilonacept) subcutaneous injection.*
FDA Label Image

Figure Bb (Arcalyst 31)

Figure Bb (Arcalyst 31)
An instructional illustration showing a hand holding a syringe at a 45-degree angle to the skin on the opposite arm, demonstrating the proper technique for subcutaneous injection.*
FDA Label Image

Figure Cc (Arcalyst 32)

Figure Cc (Arcalyst 32)
An instructional illustration showing a hand pressing a cotton ball or pad against a person's lower abdomen, with an arrow pointing upward toward an injection syringe, indicating the subcutaneous injection site area.*
FDA Label Image

Figure Dd (Arcalyst 33)

Figure Dd (Arcalyst 33)
An instructional illustration showing a vial stopper with arrows pointing to three components: a vial with a cap, a metal rod, and a syringe. This likely demonstrates parts needed or steps involved for accessing or preparing the vial contents.*
FDA Label Image

Principal Display Panel (220 mg Vial Carton)

Principal Display Panel (220 mg Vial Carton)
Packaging label for Arcalyst (rilonacept) injection, powder, lyophilized, for solution. This product is for subcutaneous use with a strength of 220 mg per vial. The label indicates refrigeration storage at 2°C to 8°C (36°F to 46°F) and protection from light. The package contains four single-dose vials and is labeled by Kiniksa Pharmaceuticals (UK), Ltd. It also includes warnings about proper use and storage.*
FDA Label Image

Principal Display Panel (220 mg Vial Carton)

Principal Display Panel (220 mg Vial Carton)
Box packaging label for Arcalyst (rilonacept) injection, powder, lyophilized for solution, 220 mg per vial. The label indicates subcutaneous use only, refrigeration requirements, and a single-dose vial. The manufacturer is Kiniksa Pharmaceuticals (UK), Ltd. The NDC number 73604-914-01 is displayed on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.